We Strive to
Make A Difference


Working for
a better future


  • An estimated 2 billion people globally have a chronic disease
  • About 35 million per year die from non-communicable diseases
  • Another 10 million die from infectious diseases
  • The world’s healthcare burden is massive and increasing


In clinical studies over the past 20 years, our licensed Immunitor oral pill immunotherapeutics have consistently proven the science and demonstrated superior safety and efficacy in diseases such as late-stage cancers, tuberculosis, HIV/AIDS, hepatitis.In many cases where other treatments have failed.

Key Capital is now working with Immunitor  towards product registrations and commercializations that will contribute to a better healthcare future.

Our Business
Recent News / media coverage
image of papers

Key Capital to Distribute Novel Immune Supplement

NEW YORK, NY, January 28, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that as SARS-CoV-2 continues to spread, and reports of increases in daily infections, hospitalizations, and deaths are becoming regular, Key Capital plans to market its Immunitor partnered potentially therapeutic oral pill as a supplement commencing early February.

Read More »